Douglas Adam Rubinson, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 29 | 2024 | 5210 | 1.600 |
Why?
|
| Carcinoma, Pancreatic Ductal | 16 | 2024 | 1605 | 1.360 |
Why?
|
| Adenocarcinoma | 12 | 2024 | 6319 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11411 | 0.430 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 3505 | 0.300 |
Why?
|
| Anus Neoplasms | 2 | 2024 | 329 | 0.280 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 1318 | 0.270 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1659 | 0.260 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 6720 | 0.220 |
Why?
|
| Hypoalbuminemia | 1 | 2023 | 86 | 0.210 |
Why?
|
| Appendiceal Neoplasms | 1 | 2023 | 145 | 0.200 |
Why?
|
| Lentivirus | 2 | 2004 | 501 | 0.190 |
Why?
|
| Disease-Free Survival | 6 | 2020 | 6870 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 5 | 2007 | 1599 | 0.190 |
Why?
|
| Esophageal Neoplasms | 2 | 2021 | 1574 | 0.180 |
Why?
|
| Palliative Care | 1 | 2015 | 3461 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 186 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5148 | 0.160 |
Why?
|
| Neutropenia | 1 | 2023 | 888 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 390 | 0.150 |
Why?
|
| Phosphoproteins | 5 | 2007 | 2440 | 0.150 |
Why?
|
| Pseudopodia | 3 | 2007 | 172 | 0.150 |
Why?
|
| RNA Interference | 2 | 2005 | 2894 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 663 | 0.150 |
Why?
|
| Jews | 1 | 2019 | 385 | 0.150 |
Why?
|
| Esophagogastric Junction | 1 | 2019 | 312 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.140 |
Why?
|
| Tricarboxylic Acids | 1 | 2016 | 29 | 0.140 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2016 | 36 | 0.140 |
Why?
|
| Microfilament Proteins | 5 | 2007 | 1150 | 0.140 |
Why?
|
| Myeloid Cells | 1 | 2020 | 801 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3693 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 506 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 564 | 0.130 |
Why?
|
| Neurites | 2 | 2007 | 378 | 0.130 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 4832 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2019 | 782 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 981 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 4013 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2019 | 534 | 0.120 |
Why?
|
| Genomics | 3 | 2023 | 5655 | 0.120 |
Why?
|
| Aged | 25 | 2023 | 162667 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2020 | 1356 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 3233 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 9124 | 0.110 |
Why?
|
| Leukocytes | 1 | 2021 | 2036 | 0.110 |
Why?
|
| Genes, Retinoblastoma | 2 | 2002 | 136 | 0.110 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2014 | 249 | 0.100 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 12328 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 1585 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1242 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 812 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2020 | 23355 | 0.100 |
Why?
|
| Humans | 45 | 2024 | 739219 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2015 | 688 | 0.090 |
Why?
|
| Middle Aged | 23 | 2023 | 212833 | 0.090 |
Why?
|
| Vitamins | 1 | 2019 | 1602 | 0.090 |
Why?
|
| Hydroxychloroquine | 1 | 2014 | 407 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2023 | 4549 | 0.090 |
Why?
|
| Pancreatectomy | 3 | 2020 | 798 | 0.090 |
Why?
|
| Weight Loss | 1 | 2020 | 2588 | 0.080 |
Why?
|
| Male | 27 | 2023 | 348967 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5500 | 0.080 |
Why?
|
| Female | 28 | 2023 | 378808 | 0.080 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 57639 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 2944 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2023 | 8395 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2021 | 10248 | 0.070 |
Why?
|
| Mutation | 8 | 2023 | 29659 | 0.070 |
Why?
|
| Vitamin D | 2 | 2019 | 3197 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2019 | 3279 | 0.070 |
Why?
|
| Autophagy | 1 | 2014 | 1291 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3453 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2022 | 1609 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2023 | 1701 | 0.070 |
Why?
|
| Smoking | 3 | 2018 | 8959 | 0.070 |
Why?
|
| Pancreas | 2 | 2024 | 1677 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 9393 | 0.060 |
Why?
|
| RNA Precursors | 2 | 2003 | 207 | 0.060 |
Why?
|
| Actins | 4 | 2007 | 2113 | 0.060 |
Why?
|
| Physiology | 1 | 2005 | 113 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 3583 | 0.060 |
Why?
|
| Therapeutics | 1 | 2005 | 116 | 0.060 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 110 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2020 | 12655 | 0.060 |
Why?
|
| Cohort Studies | 7 | 2023 | 40385 | 0.060 |
Why?
|
| Prospective Studies | 8 | 2024 | 53036 | 0.060 |
Why?
|
| Carcinoma | 1 | 2015 | 2360 | 0.060 |
Why?
|
| Edema | 2 | 2023 | 791 | 0.060 |
Why?
|
| Cytokines | 1 | 2018 | 7296 | 0.060 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 853 | 0.060 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 90 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13622 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2018 | 6537 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2727 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 2 | 2003 | 913 | 0.050 |
Why?
|
| Cerebral Cortex | 3 | 2007 | 5717 | 0.050 |
Why?
|
| Survival Rate | 4 | 2019 | 12760 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 1671 | 0.050 |
Why?
|
| Claudins | 1 | 2023 | 110 | 0.050 |
Why?
|
| Prognosis | 5 | 2023 | 28901 | 0.050 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2002 | 132 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 572 | 0.050 |
Why?
|
| Adult | 13 | 2021 | 213375 | 0.050 |
Why?
|
| Ribonucleoproteins | 1 | 2003 | 379 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2003 | 2748 | 0.050 |
Why?
|
| Proline | 1 | 2002 | 454 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 2897 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 563 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2023 | 643 | 0.050 |
Why?
|
| Embryo, Mammalian | 2 | 2007 | 1698 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2003 | 2093 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1786 | 0.050 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2000 | 72 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 647 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 449 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 5702 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2023 | 825 | 0.040 |
Why?
|
| Base Sequence | 4 | 2003 | 12807 | 0.040 |
Why?
|
| Cells, Cultured | 5 | 2007 | 19223 | 0.040 |
Why?
|
| Camptothecin | 1 | 2022 | 569 | 0.040 |
Why?
|
| Mice | 10 | 2023 | 80995 | 0.040 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 38941 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2022 | 10939 | 0.040 |
Why?
|
| Inflammation | 1 | 2018 | 10531 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 12235 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2023 | 603 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 1755 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2019 | 407 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 618 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 17384 | 0.040 |
Why?
|
| Aconitic Acid | 1 | 2016 | 14 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1369 | 0.040 |
Why?
|
| Cotinine | 1 | 2017 | 205 | 0.040 |
Why?
|
| Isocitrates | 1 | 2016 | 24 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2022 | 961 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 15500 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1821 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2021 | 1398 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2004 | 18124 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2014 | 1083 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 16624 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2000 | 910 | 0.030 |
Why?
|
| Incidence | 3 | 2020 | 20912 | 0.030 |
Why?
|
| Risk Factors | 6 | 2019 | 71972 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2019 | 11985 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3433 | 0.030 |
Why?
|
| Mice, Knockout | 4 | 2014 | 14555 | 0.030 |
Why?
|
| Cell Movement | 2 | 2007 | 5220 | 0.030 |
Why?
|
| Animals | 11 | 2023 | 168358 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6517 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2023 | 21859 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2023 | 2454 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1066 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2018 | 62691 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 2002 | 1334 | 0.030 |
Why?
|
| United States | 6 | 2018 | 69568 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 501 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2004 | 5012 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 387 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 588 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 21499 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 2013 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2023 | 6609 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3421 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 703 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 11348 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 970 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2687 | 0.030 |
Why?
|
| RNA, Fungal | 2 | 2003 | 164 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2157 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 12641 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2216 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1522 | 0.020 |
Why?
|
| Neurons | 2 | 2007 | 9340 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2000 | 1893 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 1885 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 9738 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11471 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 1998 | 0.020 |
Why?
|
| Exons | 1 | 2016 | 2432 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2024 | 76632 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2024 | 4268 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2016 | 1117 | 0.020 |
Why?
|
| DNA | 1 | 2024 | 7278 | 0.020 |
Why?
|
| Disease Progression | 2 | 2018 | 13237 | 0.020 |
Why?
|
| Stem Cells | 1 | 2003 | 3571 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1708 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 4424 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4184 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2005 | 3300 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2032 | 0.020 |
Why?
|
| Vaccination | 1 | 2021 | 3232 | 0.020 |
Why?
|
| Phenotype | 2 | 2023 | 16300 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 1 | 2007 | 45 | 0.020 |
Why?
|
| Myosin Type II | 1 | 2007 | 68 | 0.020 |
Why?
|
| Age of Onset | 1 | 2014 | 3263 | 0.020 |
Why?
|
| Growth Cones | 1 | 2007 | 117 | 0.020 |
Why?
|
| Intercellular Junctions | 1 | 2007 | 204 | 0.020 |
Why?
|
| Actomyosin | 1 | 2007 | 107 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 430 | 0.020 |
Why?
|
| DNA Primers | 2 | 2002 | 2892 | 0.020 |
Why?
|
| Chimera | 1 | 2007 | 488 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 3849 | 0.020 |
Why?
|
| Women's Health | 1 | 2016 | 2029 | 0.020 |
Why?
|
| Laminin | 1 | 2007 | 418 | 0.020 |
Why?
|
| Myosins | 1 | 2007 | 409 | 0.020 |
Why?
|
| Nurses | 1 | 2016 | 2455 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2014 | 2615 | 0.020 |
Why?
|
| Nervous System Malformations | 1 | 2007 | 244 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9708 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 4389 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2003 | 4744 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 3769 | 0.020 |
Why?
|
| Binding Sites | 2 | 2004 | 6116 | 0.020 |
Why?
|
| RNA, Transfer, Arg | 1 | 2003 | 2 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 10961 | 0.020 |
Why?
|
| Vaccinia | 1 | 2004 | 76 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2004 | 121 | 0.010 |
Why?
|
| Chromosomes, Fungal | 1 | 2003 | 111 | 0.010 |
Why?
|
| Body Patterning | 1 | 2007 | 627 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2016 | 9846 | 0.010 |
Why?
|
| Fibroblasts | 2 | 2004 | 4138 | 0.010 |
Why?
|
| Vinculin | 1 | 2002 | 62 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2007 | 1182 | 0.010 |
Why?
|
| Wiskott-Aldrich Syndrome Protein, Neuronal | 1 | 2002 | 88 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 591 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 625 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2007 | 1127 | 0.010 |
Why?
|
| Microtubules | 1 | 2007 | 1089 | 0.010 |
Why?
|
| Threonine | 1 | 2002 | 274 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2002 | 563 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 460 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2002 | 301 | 0.010 |
Why?
|
| Genotype | 1 | 2016 | 12950 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5833 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 641 | 0.010 |
Why?
|
| Ribonucleoprotein, U4-U6 Small Nuclear | 1 | 2000 | 13 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2002 | 677 | 0.010 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2000 | 36 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2002 | 752 | 0.010 |
Why?
|
| Comorbidity | 1 | 2014 | 10362 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 2833 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 489 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 940 | 0.010 |
Why?
|
| Spliceosomes | 1 | 2000 | 110 | 0.010 |
Why?
|
| Aorta | 1 | 2007 | 2047 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 1725 | 0.010 |
Why?
|
| Autoantigens | 1 | 2003 | 891 | 0.010 |
Why?
|
| Genes, Fungal | 1 | 2000 | 452 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 6391 | 0.010 |
Why?
|
| Serine | 1 | 2002 | 831 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 1883 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 3118 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 1550 | 0.010 |
Why?
|
| RNA Stability | 1 | 2000 | 322 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 3301 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2014 | 21691 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2007 | 2971 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 6473 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2016 | 12134 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2007 | 3440 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 18002 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 4454 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 3500 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4575 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 56252 | 0.010 |
Why?
|
| Heart | 1 | 2007 | 4448 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85409 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 40040 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13815 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 23292 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 20672 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 8414 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 9625 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 15982 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 4464 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 9381 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7861 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 12064 | 0.000 |
Why?
|
| Pregnancy | 1 | 2007 | 29003 | 0.000 |
Why?
|
| Rats | 1 | 2002 | 24259 | 0.000 |
Why?
|